Drugs for Hepatic Veno-Occlusive Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 49)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Inotuzumab ozogamicin |
Approved, Investigational |
Phase 4 |
|
635715-01-4 |
|
Synonyms:
BESPONSA
Besponsa®|CMC-544
CMC-544
INOTUZUMAB OZOGAMICIN
|
PF-05208773
WAY-207294
WAY-207294 CMC-544
|
|
2 |
|
Anti-Bacterial Agents |
|
Phase 4 |
|
|
|
3 |
|
Antineoplastic Agents, Immunological |
|
Phase 4 |
|
|
|
4 |
|
Immunoglobulins |
|
Phase 4 |
|
|
|
5 |
|
Antibodies |
|
Phase 4 |
|
|
|
6 |
|
Antibiotics, Antitubercular |
|
Phase 4 |
|
|
|
7 |
|
Defibrotide |
Approved, Investigational |
Phase 3 |
|
83712-60-1 |
|
Synonyms:
{5-hydroxy-4-[5-hydroxy-4-(1-methyl-1H-indol-5-yl)-4H-1,2,4-triazol-3-yl]-2-(propan-2-yl)phenoxy}phosphonate
5-Hydroxy-2-isopropyl-4-(4-(1-methyl-1H-indol-5-yl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)phenyl dihydrogen phosphate
DEFIBROTIDE
|
Defibrotide free acid
Defibrotide free acid (porcine mucosa)
Defibrotide free acid (porcine)
|
|
8 |
|
Heparin, bovine |
Approved, Investigational, Withdrawn |
Phase 3 |
|
9005-49-6 |
22833565 9812414 772 |
Synonyms:
Adomiparin
alpha-Heparin
Ariven
Arteven
Bemiparin
BOVINE HEPARIN
Calcilean
CALCIPARINE
Certoparin
CLEXANE
Clexane®|enoxaparin sodium|Lovenox®|PK-10169|RP-54563
Clivarin
Clivarine
DALTEPARIININATRIUM
Dalteparin
DALTEPARIN SODIUM
dalteparin sodium|Fragmin®
DALTEPARIN SODNÁ SŮL
DALTEPARIN SODYUM
DALTEPARINA SODICA
DALTEPARINA SÓDICA
DALTEPARINE SODIQUE
DALTÉPARINE SODIQUE
DALTEPARINNATRIUM
DALTEPARIN-NATRIUM
DALTEPARIN-NÁTRIUM
DALTEPARINO NATRIO DRUSKA
DALTEPARINUM NATRICUM
DALTEPARYNA SODOWA
Depo-Heparin
ENOXAPARIN
ENOXAPARIN SODIUM
ENOXAPARIN SODIUM (PRESERVATIVE FREE)
ENOXAPARIN SODIUM SALT
Eparina
Eparina [DCIT]
Fluxum
FR-860
FRAGMIN
Fragmin A
Fragmin B
Fraxiparin
Hed-Heparin
Hepalean
HEPARIN
Heparin Cy 216
|
HEPARIN FRAGMENT KABI 2165
Heparin Leo
Heparin Lock Flush
HEPARIN SODIUM
Heparin sodium preservative Free
Heparin sodium salt
Heparin sulfate
Heparin sulphate
Heparina
HEPARINATE
Heparine
HEPARINIC ACID
Heparinsodiumsalt
Heparinum
Hepathrom
HepFlush®
HEP-LOCK
KABI-2165
Leparan
Lipo-Hepin
LIQUAEMIN
Liquaemin Sodium
Liquemin
LOVENOX
LOVENOX (PRESERVATIVE FREE)
LOW LIQUEMINE
Low molecular weight heparin sodium
Multiparin
Novoheparin
Pabyrin
PANHEPRIN
Parnaparin
Parnaparin sodium
Parvoparin
PK-10169
Pularin
Reviparin
RP-54563
Sandoparin
SODIUM HEPARIN
Sublingula
TEDELPARIN
Thromboliquine
Unfractionated heparin
Vetren
Vitrum AB
|
|
9 |
|
Reviparin |
Approved, Investigational |
Phase 3 |
|
9041-08-1 |
|
Synonyms:
INNOHEP
Innohep®|tinzaparin sodium
LNH1
LNH-1
LOGIPARIN
|
Reviparin sodium
TINZAPARIN
Tinzaparin sodium
Tinzaparina
|
|
10 |
|
Alprostadil |
Approved, Investigational |
Phase 2, Phase 3 |
|
745-65-3 |
5280723 |
Synonyms:
(-)-3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-cyclopentaneheptanoate
(-)-3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-cyclopentaneheptanoic acid
(-)-Prostaglandin e1
(+)-3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-cyclopentaneheptanoate
(+)-3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-cyclopentaneheptanoic acid
(11a,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-en-1-Oate
(11a,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-en-1-Oic acid
(11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-en-1-Oate
(11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-en-1-Oic acid
(11Α,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-Oate
(11Α,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-Oic acid
(13E)-(15S)-11,15-Dihydroxy-9-oxoprost-13-enoate
(13E)-(15S)-11,15-Dihydroxy-9-oxoprost-13-enoic acid
(13E)-(15S)-11a,15-Dihydroxy-9-oxoprost-13-enoate
(13E)-(15S)-11a,15-Dihydroxy-9-oxoprost-13-enoic acid
(13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate
(13E)-(15S)-11-alpha,15-Dihydroxy-9-oxoprost-13-enoate
(13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoic acid
(13E)-(15S)-11-alpha,15-Dihydroxy-9-oxoprost-13-enoic acid
(13E)-(15S)-11Α,15-dihydroxy-9-oxoprost-13-enoate
(13E)-(15S)-11Α,15-dihydroxy-9-oxoprost-13-enoic acid
11,15-Dihydroxy-9-oxoprost-13-en-1-Oate
11,15-Dihydroxy-9-oxoprost-13-en-1-Oic acid
11,15-Dihydroxy-9-oxoprost-13-en-1-Oic acid (acd/name 4.0)
11a,15a-Dihydroxy-9-oxo-13-trans-prostenoate
11a,15a-Dihydroxy-9-oxo-13-trans-prostenoic acid
11alpha,15alpha-Dihydroxy-9-oxo-13-trans-prostenoate
11alpha,15alpha-Dihydroxy-9-oxo-13-trans-prostenoic acid
11Α,15α-dihydroxy-9-oxo-13-trans-prostenoate
11Α,15α-dihydroxy-9-oxo-13-trans-prostenoic acid
3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-cyclopentaneheptanoate
3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-cyclopentaneheptanoic acid
7-[(1R,2R,3R)-3-HYDROXY-2-[(1E,3S)-3-HYDROXYOCT-1-EN-1-YL]-5-OXOCYCLOPENTYL]HEPTANOIC ACID
Abbott brand OF alprostadil
Allphar brand OF alprostadil
Alprostadil
ALPROSTADIL ALFADEX
Alprostadil prostoglandin e1
Alprostadil®|MR-256|prostaglandin E<sub>1</sub>
Alprostadil(usan)
Alprostadilum
Astra brand OF alprostadil
AstraZeneca brand OF alprostadil
Befar
|
Caverject
Caverject impulse
Edex
Hoyer brand OF alprostadil
Janssen brand OF alprostadil
lipo PGE1
lipo-PGE1
L-Prostaglandin e1
Minprog
MR-256
Muse
NSC-165559
ONO-1608
Paladin brand OF alprostadil
PGE1
PGE-1
PGE₁
PGE1 Α-CD
PGE1alpha
Pharmacia brand 1 OF alprostadil
Pharmacia brand 2 OF alprostadil
Prink
PRINK (TN)
Prostaglandin e1
Prostaglandin e1alpha
Prostavasin
PROSTIN
Prostin VR
Prostin VR pediatric
Prostine VR
Schwarz brand OF alprostadil
Schwarz pharma brand OF alprostadil
Sugiran
U-10136
U-10136alprostadil
U-10136prostin
Vasaprostan
Viridal
VIRIDAL 10
VIRIDAL 20
VIRIDAL 5
VIRIDAL DUO
Vitaros
Vivus brand OF alprostadil
|
|
11 |
|
Anticoagulants |
|
Phase 3 |
|
|
|
12 |
|
Fibrinolytic Agents |
|
Phase 3 |
|
|
|
13 |
|
Platelet Aggregation Inhibitors |
|
Phase 3 |
|
|
|
14 |
|
Anti-Inflammatory Agents |
|
Phase 3 |
|
|
|
15 |
|
Coagulants |
|
Phase 3 |
|
|
|
16 |
|
Heparin, Low-Molecular-Weight |
|
Phase 3 |
|
|
|
17 |
|
Calcium heparin |
|
Phase 3 |
|
|
|
18 |
|
Cola |
|
Phase 3 |
|
|
|
19 |
|
bilirubin |
|
Phase 2, Phase 3 |
|
635-65-4 |
5280352 |
Synonyms:
(4Z,15Z)-Bilirubin ixa
(Z,Z)-Bilirubin ixa
1,10,19,22,23,24-Hexahydro-2,7,13,17-tetramethyl-1,19-dioxo-3,18-divinylbiline-8,12-dipropionate
1,10,19,22,23,24-Hexahydro-2,7,13,17-tetramethyl-1,19-dioxo-3,18-divinyl-biline-8,12-dipropionate
1,10,19,22,23,24-Hexahydro-2,7,13,17-tetramethyl-1,19-dioxo-3,18-divinylbiline-8,12-dipropionic acid
1,10,19,22,23,24-Hexahydro-2,7,13,17-tetramethyl-1,19-dioxo-3,18-divinyl-biline-8,12-dipropionic acid
2,17-Diethenyl-1,10,19,22,23,24-hexahydro-3,7,13,18-tetramethyl-1,19-dioxo-21H-biline-8,12-dipropanoate
2,17-Diethenyl-1,10,19,22,23,24-hexahydro-3,7,13,18-tetramethyl-1,19-dioxo-21H-biline-8,12-dipropanoic acid
2,7,13,17-Tetramethyl-1,19-dioxo-3,18-divinyl-1,10,19,22,23,24-hexahydro-21H-biline-8,12-dipropanoate
2,7,13,17-Tetramethyl-1,19-dioxo-3,18-divinyl-1,10,19,22,23,24-hexahydro-21H-biline-8,12-dipropanoic acid
3-(2-((3-(2-Carboxyethyl)-4-methyl-5-((3-methyl-5-oxo-4-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl)-1H-pyrrol-2-yl)methyl)-4-methyl-5-((4-methyl-5-oxo-3-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl)-1H-pyrrol-3-yl)propanoate
3-(2-((3-(2-Carboxyethyl)-4-methyl-5-((3-methyl-5-oxo-4-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl)-1H-pyrrol-2-yl)methyl)-4-methyl-5-((4-methyl-5-oxo-3-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl)-1H-pyrrol-3-yl)propanoic acid
3-(2-((3-(2-Carboxyethyl)-4-methyl-5-[(Z)-(3-methyl-5-oxo-4-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl]-1H-pyrrol-2-yl)methyl)-4-methyl-5-[(Z)-(4-methyl-5-oxo-3-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene
3-[2-[[3-(2-Carboxyethyl)-5-[(3-ethenyl-4-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(4-ethenyl-3-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoate
|
3-[2-[[3-(2-Carboxyethyl)-5-[(3-ethenyl-4-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(4-ethenyl-3-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoic acid
3-[2-[[3-(2-Carboxyethyl)-5-[(Z)-(3-ethenyl-4-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(Z)-(4-ethenyl-3-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoate
3-[2-[[3-(2-Carboxyethyl)-5-[(Z)-(3-ethenyl-4-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(Z)-(4-ethenyl-3-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoic acid
8,12-Bis(2-carboxyethyl)-2,7,13,17-tetramethyl-3,18-divinylbiladiene-ac-1,19(21H,24H)-dione
BILIRUBIN
Bilirubin IX alpha
Bilirubin ixalpha
Bilirubin IX-alpha
Bilirubin(Z,Z)
Bilirubin-ixalpha
Cholerythrin
Hematoidin
NSC-26685
|
|
20 |
|
Orange |
Approved |
Phase 1, Phase 2 |
|
|
|
21 |
|
Acetylcysteine |
Approved, Investigational |
Phase 2 |
|
616-91-1 |
581 12035 |
Synonyms:
(2R)-2-ACETAMIDO-3-SULFANYLPROPANOIC ACID
(2R)-2-Acetylamino-3-sulfanylpropanoate
(2R)-2-Acetylamino-3-sulfanylpropanoic acid
(2R)-2-Acetylamino-3-sulphanylpropanoate
(2R)-2-Acetylamino-3-sulphanylpropanoic acid
(R)-2-Acetylamino-3-mercaptopropanoate
(R)-2-Acetylamino-3-mercaptopropanoic acid
(R)-Mercaptate
(R)-Mercaptic acid
(R)-Mercapturic acid
2-[(1-Hydroxyethylidene)amino]-3-sulfanylpropanoate
2-[(1-Hydroxyethylidene)amino]-3-sulphanylpropanoate
2-[(1-Hydroxyethylidene)amino]-3-sulphanylpropanoic acid
2-acetylamino-3-mercapto-Propionate
2-acetylamino-3-mercapto-Propionic acid
5052
Ac pharma brand OF acetylcysteine
ACC
ACC-600
Acebraus
Acemuc
Acetabs
Acetadote
Acetilcisteina
Acetylcystein al
Acetylcystein atid
Acetylcystein heumann
Acetylcystein trom
Acetylcystein, mentopin
Acetylcysteine
Acetylcysteine ac-pharma brand
Acetylcysteine alcon brand
Acetylcysteine aluid brand
Acetylcysteine atid brand
Acetylcysteine azupharma brand
Acetylcysteine betapharm brand
Acetylcysteine bioiberica brand
Acetylcysteine bouchara brand
Acetylcysteine centrafarm brand
Acetylcysteine disphar brand
Acetylcysteine farmasan brand
Acetylcysteine fresenius brand
Acetylcysteine génévrier brand
Acétylcystéine GNR
Acetylcysteine GNR-pharma brand
Acetylcysteine guerbet brand
Acetylcysteine hermes brand
Acetylcysteine heumann brand
Acetylcysteine hydrochloride
Acetylcysteine inpharzam brand
Acetylcysteine intra brand
Acetylcysteine klinge brand
Acetylcysteine krewel brand
Acetylcysteine lichtenstein brand
Acetylcysteine lindopharm brand
Acetylcysteine merck brand
Acetylcysteine oberlin brand
Acetylcysteine pfleger brand
Acetylcysteine pharbita brand
Acetylcysteine roberts brand
Acetylcysteine sodium
Acetylcysteine temmler brand
Acetylcysteine teva brand
Acetylcysteine thiemann brand
Acetylcysteine trommsdorff brand
Acetylcysteine upsa brand
Acetylcysteine whitehall brand
Acetylcysteine zambon brand
Acetylcysteine zinc
Acetylcysteine zyma brand
Acetylcysteine, (D)-isomer
Acetylcysteine, (DL)-isomer
Acetylcysteine, monoammonium salt
Acetylcysteine, monosodium salt
Acetylcysteinum
Acetylin
Acetyst
Acid, mercapturic
Ac-pharma brand OF acetylcysteine
A-CYS
Airbron
Alcon brand OF acetylcysteine
Allen and hanburys brand OF acetylcysteine
Aluid brand OF acetylcysteine
Alveolex
Atid brand OF acetylcysteine
Azubronchin
Azupharma brand OF acetylcysteine
Betapharm brand OF acetylcysteine
Bioiberica brand OF acetylcysteine
Bisolvon nac
Boehringer ingelheim brand OF acetylcysteine
Bouchara brand OF acetylcysteine
Bristol myers squibb brand OF acetylcysteine
Bristol myers squibb brand OF acetylcysteine sodium salt
Bristol-myers squibb brand OF acetylcysteine
Bristol-myers squibb brand OF acetylcysteine sodium salt
Bromuc
broncho Fips
broncho-Fips
BronchoFips
Broncholysin
Broncoclar
Centrafarm brand OF acetylcysteine
CETYLEV
Codotussyl
Cystamucil
dampo Mucopect
|
Dey brand OF acetylcysteine sodium salt
Disphar brand OF acetylcysteine
Durabronchal
EN-CYS
Eurespiran
Exomuc
Fabrol
Farmasan brand OF acetylcysteine
Fluimicil infantil
Fluimucetin
Fluimucil
FLUIMUCIL 600
FLUIMUCIL LONG
FLUIMUCIL N
Flumucetin
Fluprowit
Frekatuss
Fresenius brand OF acetylcysteine
Genac
Génévrier brand OF acetylcysteine
GNR Pharma brand OF acetylcysteine
GNR-Pharma brand OF acetylcysteine
Guerbet brand OF acetylcysteine
Hermes brand OF acetylcysteine
Heumann brand OF acetylcysteine
Hoestil
Hustengetränk, optipect
Hydrochloride, acetylcysteine
Ilube
Inpharzam brand OF acetylcysteine
Intra brand OF acetylcysteine
Jenacystein
Jenapharm
Klinge brand OF acetylcysteine
Krewel brand OF acetylcysteine
L-a-Acetamido-b-mercaptopropionate
L-a-Acetamido-b-mercaptopropionic acid
L-Acetylcysteine
L-alpha-Acetamido-beta-mercaptopropionate
L-alpha-Acetamido-beta-mercaptopropionic acid
Lantamed
Larylin nac
Lichtenstein brand OF acetylcysteine
Lindocetyl
Lindopharm brand OF acetylcysteine
Lysox
L-Α-acetamido-β-mercaptopropionate
L-Α-acetamido-β-mercaptopropionic acid
m Pectil
Mentopin acetylcystein
Mercaptate
Mercaptic acid
Mercapturic acid
Merck brand OF acetylcysteine
Monoammonium salt acetylcysteine
Monosodium salt acetylcysteine
m-Pectil
MPectil
Muciteran
muco Sanigen
Mucolysin
Mucomyst
Mucopect, dampo
Mucosil
MUCOSIL-10
MUCOSIL-20
Mucosol
Mucosolvin
N Acetyl L cysteine
N Acetylcysteine
NAC
NAC al
NAC zambon
NAC, bisolvon
N-Acetyl-3-mercaptoalanine
N-Acetylcysteine
N-Acety-L-cysteine
N-Acetyl-L-(+)-cysteine
N-Acetyl-L-cysteine
NSC-111180
Oberlin brand OF acetylcysteine
Optipect hustengetränk
ORONAC 600
PARVOLEX
Pfleger brand OF acetylcysteine
Pharbita brand OF acetylcysteine
Produpharm lappe brand OF acetylcysteine
RESPI-NAC
Roberts brand OF acetylcysteine
Roche nicholas brand OF acetylcysteine
Sanigen, muco
Siccoral
Siran
Sodium 2-acetamido-3-mercaptopropionate
Sodium, acetylcysteine
Solmucol
Temmler brand OF acetylcysteine
Teva brand OF acetylcysteine
Thiemann brand OF acetylcysteine
Trommsdorff brand OF acetylcysteine
UPSA brand OF acetylcysteine
Whitehall brand OF acetylcysteine
YOURNAC
Zambon brand OF acetylcysteine
Zambon, nac
Zinc, acetylcysteine
Zyma brand OF acetylcysteine
|
|
22 |
|
Imatinib Mesylate |
|
Phase 1, Phase 2 |
|
220127-57-1 |
|
Synonyms:
GLEEVEC
GLIVEC
IMATINIB MESILATE
IMATINIB MESYLATE
|
IMATINIB METHANESULFONATE
STI571
STI-571
|
|
23 |
|
Protein Kinase Inhibitors |
|
Phase 1, Phase 2 |
|
|
|
24 |
|
HIV Protease Inhibitors |
|
Phase 2 |
|
|
|
25 |
|
Serine Proteinase Inhibitors |
|
Phase 2 |
|
|
|
26 |
|
Antithrombins |
|
Phase 2 |
|
|
|
27 |
|
Antithrombin III |
|
Phase 2 |
|
|
|
28 |
|
protease inhibitors |
|
Phase 2 |
|
|
|
Synonyms:
|
29 |
|
Antiviral Agents |
|
Phase 2 |
|
|
|
30 |
|
Anti-Infective Agents |
|
Phase 2 |
|
|
|
31 |
|
Expectorants |
|
Phase 2 |
|
|
|
32 |
|
Antidotes |
|
Phase 2 |
|
|
|
33 |
|
Pharmaceutical Solutions |
|
Phase 2 |
|
|
|
34 |
|
N-monoacetylcystine |
|
Phase 2 |
|
|
|
35 |
|
Respiratory System Agents |
|
Phase 2 |
|
|
|
36 |
|
Antioxidants |
|
Phase 2 |
|
|
|
37 |
|
Protective Agents |
|
Phase 2 |
|
|
|
38 |
|
Serine |
Investigational, Nutraceutical |
Phase 2 |
|
56-45-1 |
5951 |
Synonyms:
(-)-Serine
(2S)-2-Amino-3-hydroxypropanoate
(2S)-2-Amino-3-hydroxypropanoic acid
(3R,3'r,6S)-4,5-DIDEHYDRO-5,6-dihydro-b,b-carotene-3,3'-diol
(3R,3'r,6S)-4,5-DIDEHYDRO-5,6-dihydro-BETA,BETA-carotene-3,3'-diol
(3R,3'r,6S)-4,5-DIDEHYDRO-5,6-dihydro-β,β-carotene-3,3'-diol
(S)-(-)-Serine
(S)-2-Amino-3-hydroxypropanoate
(S)-2-Amino-3-hydroxy-propanoate
(S)-2-Amino-3-hydroxypropanoic acid
(S)-2-Amino-3-hydroxy-propanoic acid
(S)-a-Amino-b-hydroxypropionate
(S)-a-Amino-b-hydroxypropionic acid
(S)-alpha-Amino-beta-hydroxypropionate
(S)-alpha-Amino-beta-hydroxypropionic acid
(S)-b-Amino-3-hydroxypropionate
(S)-b-Amino-3-hydroxypropionic acid
(S)-beta-Amino-3-hydroxypropionate
(S)-beta-Amino-3-hydroxypropionic acid
(S)-Serine
(S)-Α-amino-β-hydroxypropionate
(S)-Α-amino-β-hydroxypropionic acid
2-Amino-3-hydroxypropanoate
2-Amino-3-hydroxypropanoic acid
3-Hydroxy-L-alanine
|
alpha-Amino-beta-hydroxypropionic acid
beta-Hydroxyalanine
beta-Hydroxy-L-alanine
b-Hydroxyalanine
b-Hydroxy-L-alanine
Bo-xan
e 161b
L Serine
L-(-)-Serine
L-2-Amino-3-hydroxypropionate
L-2-Amino-3-hydroxypropionic acid
L-3-Hydroxy-2-aminopropionate
L-3-Hydroxy-2-aminopropionic acid
L-3-Hydroxy-alanine
L-Ser
L-Serin
L-Serine
S
Ser
Serina
SERINE
Serinum
Xanthophyll
Β-hydroxyalanine
Β-hydroxy-L-alanine
|
|
39 |
|
Oxaliplatin |
Approved, Investigational |
|
|
61825-94-3 |
43805 11947679 6857599 |
Synonyms:
ACT 078
ACT-078
DACPLAT
Diaminocyclohexane Oxalatoplatinum
Eloxatin
Eloxatine
Elplat
Foloxatine
JM-83
L-OHP
L-OHP CPD
MBP-426 (LIPOSOMAL OXALIPLATIN)
NSC-266046
Oxalatoplatin
|
Oxalatoplatinum
Oxaliplatin
Oxaliplatin [Usan:Inn:Ban]
oxaliplatine
oxaliplatino
Oxaliplatino [Spanish]
oxaliplatinum
Oxaliplatinum [Latin]
Oxaloplatine [French]
Oxaloplatino [Spanish]
RP-54780
SR-96669
Transplatin
|
|
40 |
|
Bevacizumab |
Approved, Investigational |
|
|
216974-75-3 |
135329020 |
Synonyms:
12-IGG1
ANTIVEGF
Anti-VEGF Humanized Monoclonal Antibody
Anti-VEGF monoclonal antibody
AVA-1
AVASTIN
Bevacizumab
BEVACIZUMAB BETA
bevacizumab-awwb
|
BI 695502
BS-503A
FKB-238
HLX04
HLX-04
R-435
RG-435
RHUMAB-
rhuMAb-VEGF
|
|
41 |
|
Protein C |
Approved |
|
|
|
|
Synonyms:
autoprothrombin IIA
blood coagulation factor XIV
Human protein C
Protein C (coagulation inhibitor)
|
Protein C concentrate
Protein C concentrate (human)
Protein C concentrate human
Protein C human
|
|
42 |
|
Atezolizumab |
Approved, Investigational |
|
|
1380723-44-3 |
|
Synonyms:
ANTI-PDL1
ANTI-PD-L1
ATEZOLIZUMAB
MPDL3280A
|
MPDL-3280A
RG-7446
TECENTRIQ
|
|
43 |
|
L-Glutamine |
Approved, Investigational, Nutraceutical |
|
|
56-85-9 |
5961 |
Synonyms:
(2S)-2,5-Diamino-5-oxopentanoate
(2S)-2,5-DIAMINO-5-OXOPENTANOIC ACID
(2S)-2-Amino-4-carbamoylbutanoate
(2S)-2-AMINO-4-CARBAMOYLBUTANOIC ACID
(S)-2,5-Diamino-5-oxopentanoate
(S)-2,5-DIAMINO-5-OXOPENTANOIC ACID
[<sup>14</sup>C]-glutamine
[<sup>3</sup>H]-glutamine
2-Aminoglutaramic acid
Cebrogen
D Glutamine
D-Glutamine
ENDARI
FEMA NO. 3684
gamma-Glutamine
Glavamin
GLN
Glumin
Glutamate 5-amide
Glutamate amide
GLUTAMIC ACID 5-AMIDE
GLUTAMIC ACID AMIDE
Glutamina
GLUTAMINE
L Glutamine
L-(+)-GLUTAMINE
|
L-2-Aminoglutaramate
L-2-AMINOGLUTARAMIC ACID
L-2-Aminoglutaramidic acid
Levoglutamid
Levoglutamida
LEVOGLUTAMIDE
Levoglutamidum
Levoglutamina
L-Glutamate g-amide
L-Glutamate gamma-amide
L-Glutamate γ-amide
L-Glutamic acid 5-amide
L-Glutamic acid g-amide
L-GLUTAMIC ACID GAMMA-AMIDE
L-GLUTAMIC ACID Γ-AMIDE
L-Glutamid
L-Glutamide
L-GLUTAMIN
L-GLUTAMINE
L-GLUTAMINSAEURE-5-AMID
L-GLUTAMINSÄURE-5-AMID
NSC-27421
NUTRESTORE
Polyglutamine
Q
Stimulina
|
|
44 |
|
Antimitotic Agents |
|
|
|
|
|
45 |
|
Angiogenesis Inhibitors |
|
|
|
|
|
46 |
|
Factor VIII |
|
|
|
|
|
47 |
|
Protein S |
|
|
|
|
|
48 |
|
Antibodies, Monoclonal |
|
|
|
|
|
49 |
|
Immunologic Factors |
|
|
|
|
|
Interventional clinical trials:
(show all 35)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Using Ultrasound Elastography to Predict Development of Sinusoidal Obstruction Syndrome |
Active, not recruiting |
NCT03858530 |
Phase 4 |
|
2 |
A PHASE 4, OPEN-LABEL, RANDOMIZED STUDY OF TWO INOTUZUMAB OZOGAMICIN DOSE LEVELS IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA ELIGIBLE FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION AND WHO HAVE RISK FACTOR(S) FOR VENO-OCCLUSIVE DISEASE |
Active, not recruiting |
NCT03677596 |
Phase 4 |
inotuzumab ozogamicin-dose level 2;Inotuzumab ozogamicin-dose level 1 |
3 |
Validating Ultrasound Biomarkers for Hepatic Sinusoidal Obstruction Syndrome in Pediatric Hematopoietic Cell Transplant Patients |
Withdrawn |
NCT03963999 |
Phase 4 |
Contrast Enhanced Ultrasound (CEUS) |
4 |
Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study |
Completed |
NCT00628498 |
Phase 3 |
Defibrotide |
5 |
Prospective Randomized Study of the Incidence and Outcome of Veno-Occlusive Disease (VOD) With the Prophylactic Use of Defibrotide (DF) in Pediatric Stem Cell Transplantation |
Completed |
NCT00272948 |
Phase 2, Phase 3 |
Defibrotide |
6 |
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy |
Completed |
NCT00358501 |
Phase 3 |
Defibrotide |
7 |
A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant |
Completed |
NCT02851407 |
Phase 3 |
Defibrotide |
8 |
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters |
Completed |
NCT00006083 |
Phase 3 |
Fragmin |
9 |
Phase III Double-Blind Trial Comparing Low-Molecular Weight Heparin (LMWH) Versus Placebo in Patients With Advanced Cancer |
Completed |
NCT00003674 |
Phase 3 |
dalteparin;standard therapy |
10 |
Pharmacokinetic Study of Lipo-PGE1 for Prevention of VOD After HSCT |
Active, not recruiting |
NCT02338440 |
Phase 2, Phase 3 |
lipoprostaglandin E1 |
11 |
Defibrotide for Hematopoietic Stem Cell Transplant Patients With Severe Hepatic Venocclusive Disease: A Phase I/II Study to Determine the Minimal Effective Dose |
Completed |
NCT00003966 |
Phase 2 |
defibrotide |
12 |
Adjunct Targeted Biologic Inhibition in Children With Multivessel Intraluminal Pulmonary Vein Stenosis |
Completed |
NCT00891527 |
Phase 1, Phase 2 |
Bevacizumab (Avastin) and Imatinib Mesylate (Gleevec) |
13 |
Phase II Open Label Study to Assess Efficacy of 5-day Defibrotide Treatment for Hepatic SOS/VOD |
Recruiting |
NCT04313036 |
Phase 2 |
Defibrotide |
14 |
Antithrombin-III for Patients With Hepatic Veno-occlusive Diseases Following Hematopoietic Stem Cell Transplantation |
Active, not recruiting |
NCT01886248 |
Phase 2 |
Freeze-dried Concentrated Human Antithrombin Ⅲ 500 IU |
15 |
Prospective, Randomized Study Using N-Acetylcysteine as Prophylaxis of Sinusoidal Obstruction Syndrome in Patients Undergoing Hematopoietic Stem Cell Transplantation |
Not yet recruiting |
NCT04712435 |
Phase 2 |
N-acetylcysteine;Placebo |
16 |
Hepatic Artery Infusion of CD34+ Cells, Isolated by the Isolex 300i Device, in Stem Cell Transplant Recipients With Hepatic Failure Due to Veno-occlusive Disease |
Withdrawn |
NCT00062543 |
Phase 1 |
|
17 |
Pharmacogenetic Study of Antimitotic Therapies Involved in Hepatic Veno-occlusive Disease in Children With Nephroblastoma or Acute Lymphoblastic Leukemia |
Unknown status |
NCT04168788 |
|
|
18 |
A Randomized Control Studies on the Effects of Glutamine on the Clinical Outcome of Bone Marrow Transplant Recipients With Special Reference to Veno-occlusive Disease and Mucositis. |
Unknown status |
NCT00563498 |
|
Glutamine |
19 |
A Multi-centre, Multinational, Prospective Observational Registry to Collect Safety and Outcome Data in Patients Diagnosed With Severe Hepatic Veno-occlusive Disease (VOD) Following Hematopoietic Stem Cell Transplantation (HSCT) and Treated With Defitelio® |
Completed |
NCT03032016 |
|
|
20 |
A Retrospective Study About Detection of Sinusoidal Obstruction Syndrome With Ultrasound After Allogeneic Hematopoietic Stem Cell Transplantation |
Completed |
NCT04141735 |
|
|
21 |
Using Ultrasound Elastography to Predict Development of Sinusoidal Obstruction Syndrome |
Completed |
NCT02483481 |
|
|
22 |
Usefulness of Liver Stiffness Measurement in Predicting Hepatic Veno-Occlusive Disease Development in Patients Who Undergo HSCT: a Multicentric Prospective Study |
Completed |
NCT03426358 |
|
|
23 |
Prevention of the Hepatic Sinusoidal Obstruction Syndrome Secondary to Oxaliplatin-based Neoadjuvant Chemotherapy for Colorectal Liver Metastases by Means of Anticoagulants |
Completed |
NCT00885950 |
|
|
24 |
Pharmacogenetics of Veno-Occlusive Disease (VOD) in Children With Haematological Stem Cell Transplantation (HSCT) |
Completed |
NCT03664427 |
|
|
25 |
To Compare "Balloon Occluded Thrombolysis" With "Conventional Catheter Directed Thrombolysis" in Thrombotically Occluded DIPSS Stent in Patients of Budd- Chiari Syndrome. |
Completed |
NCT05117684 |
|
|
26 |
Balloon Angioplasty Alone Versus in Combination With Stent Placement for the Treatment of Budd-Chiari Syndrome in China: An Randomized Controlled Trial |
Completed |
NCT02201485 |
|
|
27 |
Using Ultrasound Elastography to Predict Development of Hepatic Sinusoidal Obstruction Syndrome |
Recruiting |
NCT03865589 |
|
|
28 |
A Prospective Registry of Pediatric Cellular Therapy Patients at Risk for Endothelial Dysfunction, Sinusoidal Obstruction Syndrome and/or Multi-Organ Dysfunction Syndrome (MODS). |
Recruiting |
NCT05090345 |
|
|
29 |
Prospective Evaluation of Coagulation Status and Thromboelastometry Guided Management of Genetic and Acquired Thrombophilia in Patients With Portal Vein Thrombosis and Budd-Chiari Syndrome |
Recruiting |
NCT05123326 |
|
|
30 |
Vienna Vascular Liver Disease Study: Characterization of Patients With Vascular Liver Disease - a Registry With Biobank |
Recruiting |
NCT03541057 |
|
|
31 |
A Multicenter, Randomized, Open-label Study Evaluating the Efficacy and Safety of Hepatic Resection for Hepatocellular Carcinoma With Venous Tumor Thrombosis After Initial Atezolizumab Plus Bevacizumab Treatment |
Recruiting |
NCT04649489 |
|
Atezolizumab |
32 |
Biomarkers of Endothelial Dysfunction in Pediatric Patients Receiving High Intensity Chemotherapy/Irradiation |
Active, not recruiting |
NCT03132337 |
|
|
33 |
Compassionate Use of Defibrotide for Patients With Veno-Occlusive Disease |
No longer available |
NCT00143546 |
|
Defibrotide |
34 |
Defibrotide Compassionate Use Protocol for Patients With Life Threatening Veno-Occlusive Disease of the Liver |
No longer available |
NCT00263978 |
|
Defibrotide |
35 |
Portal Vein Thrombosis in Cirrhosis: A Cohort Sudy |
Withdrawn |
NCT02275585 |
|
|
Inferred drug relations via
UMLS
71
/
NDF-RT
50
:
Antithrombin III, Human
|
ANTITHROMBIN III,RECOMBINANT
|
|